Addressing unmet needs in the treatment of COPD

European Respiratory Review

Volumn 23, Issue 133, 2014, Pages 333-344

  Patalano, Francesco ^a   Banerji, Donald ^a   D'Andrea, Peter ^a   Fogel, Robert ^a   Altman, Pablo ^a   Colthorpe, Paul ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT;

ASTHMA; DIFFERENTIAL DIAGNOSIS; HUMAN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ASTHMA; BRONCHODILATOR AGENTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84906890734     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00004014     Document Type: Review

References (101)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. www.goldcopd.org/uploads/users/files/GOLD_Report_2014.pdf Date last updated: 2014. Date last accessed: January 21, 2014.
2. Lundbäck B, Lindberg A, Lindström M, et al. Not 15 but 50% of smokers develop COPD? - Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003; 97: 115-122.
3. Boutayeb A, Boutayeb S. The burden of non communicable diseases in developing countries. Int J Equity Health 2005; 4: 2.
4. World Health Organization. Gender, women, and the tobacco epidemic. Geneva, WHO, 2010.
5. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442.
6. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998; 4: 1241-1243.
7. Lou P, Zhu Y, Chen P, et al. Vulnerability, beliefs, treatments and economic burden of chronic obstructive pulmonary disease in rural areas in China: a cross-sectional study. BMC Public Health 2012; 12: 287.
8. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
9. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182: 598-604.
10. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365: 1184-1192.
11. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10: 59.
12. Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171-1178.
13. Decramer M, Cooper CB. Treatment of COPD: the sooner the better? Thorax 2010; 65: 837-841.
14. Mahler DA, Ward J, Waterman LA, et al. Patient-reported dyspnea in COPD reliability and association with stage of disease. Chest 2009; 136: 1473-1479.
15. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001; 56: 880-887.
16. Miravitlles M, Soriano JB, García-Río F, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax 2009; 64: 863-868.
17. Watz H, Waschki B, Meyer T, et al. Physical activity in patients with COPD. Eur Respir J 2009; 33: 262-272.
18. Watz H, Waschki B, Boehme C, et al. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit Care Med 2008; 177: 743-751.
19. Troosters T, Sciurba F, Battaglia S, et al. Physical inactivity in patients with COPD, a controlled multi-center pilot-study. Respir Med 2010; 104: 1005-1011.
20. Cooper CB. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med 2006; 119: 21-31.
21. Decramer M, Rossi A, Lawrence D, et al. Indacaterol therapy in patients with COPD not receiving other maintenance treatment. Respir Med 2012; 106: 1706-1714.
22. Decramer M, Dahl R, Kornmann O, et al. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use. Respir Med 2013; 107: 223-232.
23. D'Urzo A, Kerwin E, Overend T, et al. Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies. Curr Med Res Opin 2014; 30: 493-508.
24. Kerstjens H, Kornmann O, Deslée G, et al. Once-daily indacaterol 150mg or 300mg and other bronchodilators in COPD patients of GOLD 2011 groups A and B. Eur Respir J 2013; 42: Suppl. 57, 144s.
25. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-338.
26. Mapel DW, Dalal AA, Blanchette CM, et al. Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims. Int J Chron Obstruct Pulmon Dis 2011; 6: 573-581.
27. Price D, Brusselle G. Challenges of COPD diagnosis. Expert Opin Med Diagn 2013; 7: 543-556.
28. Global Initiative for Asthma. Global strategy for asthma management and prevention. USA, GINA, 2012.
29. Melbye H, Drivenes E, Dalbak LG, et al. Asthma, chronic obstructive pulmonary disease, or both? Diagnostic labeling and spirometry in primary care patients aged 40 years or more. Int J Chron Obstruct Pulmon Dis 2011; 6: 597-603.
30. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009; 64: 728-735.
31. Global Initiative for Asthma. Global strategy for asthma management and prevention. www.ginasthma.org/local/uploads/files/GINA_Report_2014.pdf Date last updated: May 2014. Date last accessed: May 12, 2014.
32. Soriano JB, Davis KJ, Coleman B, et al. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest 2003; 124: 474-481.
33. Hardin M, Silverman EK, Barr RG, et al. The clinical features of the overlap between COPD and asthma. Respir Res 2011; 12: 127.
34. Miravitlles M, Soriano JB, Ancochea J, et al. Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status. Respir Med 2013; 107: 1053-1060.
35. Menezes AM, Montes de Oca M, Pérez-Padilla R, et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest 2014; 145: 297-304.
36. Lapperre TS, Postma DS, Gosman MM, et al. Relation between duration of smoking cessation and bronchial inflammation in COPD. Thorax 2006; 61: 115-121.
37. Willemse BW, ten Hacken NH, Rutgers B, et al. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 2005; 26: 835-845.
38. Willemse BW, ten Hacken NH, Rutgers B, et al. Smoking cessation improves both direct and indirect airway hyperresponsiveness in COPD. Eur Respir J 2004; 24: 391-396.
39. Wise RA, Kanner RE, Lindgren P, et al. The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD: the Lung Health Study. Chest 2003; 124: 449-458.
40. Lapperre TS, Sont JK, van Schadewijk A, et al. Smoking cessation and bronchial epithelial remodelling in COPD: a cross-sectional study. Respir Res 2007; 8: 85.
41. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188: e13-e64.
42. Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127: 809-817.
43. Smith SM, Elkin SL, Partridge MR. Technology and its role in respiratory care. Prim Care Respir J 2009; 18: 159-164.
44. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
45. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009; 34: 641-647.
46. Yawn BP, Li Y, Tian H, et al. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int J Chron Obstruct Pulmon Dis 2013; 8: 295-304.
47. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010; 123: 1001-1006.
48. Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 2011; 66: 699-708.
49. Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2013; 131: 636-645.
50. Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med 2012; 106: 989-997.
51. Vestbo J, Vogelmeier C, Small M, et al. Understanding the GOLD 2011 strategy as applied to a real-world COPD population. Respir Med 2014; 105: 729-736.
52. Jochmann A, Neubauer F, Miedinger D, et al. General practitioners' adherence to the COPD GOLD guidelines: baseline data from the Swiss COPD Cohort Study. Swiss Med Wkly 2010; 140: W13053.
53. Small M, Broomfield S, Higgins V. Quantification and treatment patterns of real-world patients classified by the GOLD 2011 strategy. Eur Respir J 2012; 40: Suppl. 56, 524s.
54. Nascimento OA, Camelier A, Rosa FW, et al. Chronic obstructive pulmonary disease is underdiagnosed and undertreated in Sao Paulo (Brazil): results of the PLATINO study. Braz J Med Biol Res 2007; 40: 887-895.
55. Peña VS, Miravitlles M, Gabriel R, et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest 2000; 118: 981-989.
56. Coultas DB, Mapel D, Gagnon R, et al. The health impact of undiagnosed airflow obstruction in a national sample of United States adults. Am J Respir Crit Care Med 2001; 164: 372-377.
57. Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis 2014 [In press].
58. Han MK, Muellerova H, Curran-Everett D, et al. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med 2013; 1: 43-50.
59. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med 2012; 186: 975-981.
60. Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J 2013; 42: 636-646.
61. Soriano JB, Alfageme I, Almagro P, et al. Distribution and prognostic validity of the new Global initiative for chronic Obstructive Lung Disease grading classification. Chest 2013; 143: 694-702.
62. Agusti A, Hurd S, Jones P, et al. FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J 2013; 42: 1391-1401.
63. Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J 2013; 41: 1252-1256.
64. McKeage K. Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease. Drugs 2012; 72: 543-563.
65. Cazzola M, Bardaro F, Stirpe E. The role of indacaterol for chronic obstructive pulmonary disease (COPD). J Thorac Dis 2013; 5: 559-566.
66. Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo- controlled comparison. Eur Respir J 2011; 37: 273-279.
67. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010; 65: 473-479.
68. Buhl R, Dunn LJ, Disdier C, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011; 38: 797-803.
69. Vogelmeier C, Ramos-Barbon D, Jack D, et al. Indacaterol provides 24-hour bronchodilation in COPD: a placebo- controlled blinded comparison with tiotropium. Respir Res 2010; 11: 135.
70. Novartis. Novartis' INSTEAD study for Onbrez1 Breezhaler1 in patients with moderate COPD meets primary objective. www.novartis.com/newsroom/media-releases/en/2014/1779880.shtml Date last updated: April 25, 2014. Date last accessed: April 30, 2014.
71. D'Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate- to-severe COPD: the GLOW1 trial. Respir Res 2011; 12: 156.
72. Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 2012; 40: 1106-1114.
73. Beeh KM, Singh D, Di Scala L, et al. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis 2012; 7: 503-513.
74. Chapman KR, Beeh KM, Beier J, et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once- daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med 2014; 14: 4.
75. Clinicaltrials.gov. Efficacy, tolerability and safety of NVA237 in patients with chronic obstructive pulmonary disease. NCT01513460. http://clinicaltrials.gov/ct2/show/NCT01513460?term5NCT01513460&rank51 Date last updated: January 27, 2014. Date last accessed: March 14, 2014.
76. Mahler DA, D'Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012; 67: 781-788.
77. Vincken W, Aumann J, Chen H, et al. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chron Obstruct Pulmon Dis 2014; 9: 215-218.
78. Cazzola M, Molimard M. The scientific rationale for combining long-acting b2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010; 23: 257-267.
79. Yu AP, Guérin A, de Leon DP, et al. Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. Respir Med 2011; 105: 1861-1871.
80. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013; 42: 1484-1494.
81. Mahler DA, Decramer M, D'Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE study. Eur Respir J 2014; 43: 1599-1609.
82. Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013; 1: 51-60.
83. Novartis. Novartis once-daily Ultibro1 Breezhaler1 showed superior efficacy versus Seretide1 for COPD patients in second head-to-head study. www.novartis.com/newsroom/media-releases/en/2014/1781026.shtml Date last updated: April 30, 2014. Date last accessed: April 30, 2014.
84. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double- blind, parallel-group study. Lancet Respir Med 2013; 1: 199-209.
85. Banerji D, Alagappan V, Green Y, et al. Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials. Eur Respir J 2013; 42: Suppl. 57, 693s.
86. Banerji D, Fogel R, Beeh KM. Dual bronchodilation for the treatment of chronic obstructive pulmonary disease: a review of the latest clinical data. Clin Investig 2014 [In press DOI: 110.1183/09031936.00124013].
87. Ferguson GT, Barnes N, Mehta R, et al. Cardio- and cerebro-vascular safety of QVA149: Results from a pooled analysis. Eur Respir J 2013; 42: Suppl. 57, 878s.
88. Welte T, Vogelmeier C, Dahl R, et al. Once-daily QVA149 has a good safety profile in patients with COPD. Eur Respir J 2013; 42: Suppl. 57, 143s-144s.
89. Clinicaltrials.gov. QVA vs. salmeterol/fluticasone, 52-week exacerbation study. NCT01782326. http://clinicaltrials.gov/ct2/show/NCT01782326?term501782326&rank51 Date last updated: August 20, 2013. Date last accessed: December 5, 2013.
90. Clinicaltrials.gov. Comparison of long-term safety of the combination product QVA149A against placebo and standard of care treatment in chronic obstructive pulmonary disease patients with moderate to severe airflow limitation. NCT01610037. http://clinicaltrials.gov/ct2/show/NCT01610037?term501610037&rank51 Date last updated: July 15, 2013. Date last accessed: December 5, 2013.
91. Colthorpe P, Voshaar T, Kiekbusch T, et al. Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium. J Drug Assess 2013; 2: 11-16.
92. Pavkov R, Mueller S, Fiebich K, et al. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr Med Res Opin 2010; 26: 2527-2533.
93. Jones PW, Beeh KM, Chapman KR, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 2014; 189: 250-255.
94. Hughes AD, McNamara A, Steinfeld T. Multivalent dual pharmacology muscarinic antagonist and b2 agonist (MABA) molecules for the treatment of COPD. Prog Med Chem 2012; 51: 71-95.
95. Wouters EF, Postma DS, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005; 60: 480-487.
96. Nadeem NJ, Taylor SJ, Eldridge SM. Withdrawal of inhaled corticosteroids in individuals with COPD - a systematic review and comment on trial methodology. Respir Res 2011; 12: 107.
97. Rossi A, Guerriero M, Corrado A. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res 2014; 15: 77.
98. Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012; 7: e37483.
99. Clinicaltrials.gov. Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD) (COPDGene). NCT00608764. http://clinicaltrials.gov/ct2/show/NCT00608764?term5NCT00608764&rank51 Date last updated: July 22, 2013. Date last accessed: July 14, 2014.
100. Clinicaltrials.gov. The MRC/ABPI COPD Cohort v1.7 (COPDMAP). NCT01620645. http://clinicaltrials.gov/ct2/show/NCT01620645?term5NCT01620645&rank51 Date last accessed: July 14, 2014.
101. Clinicaltrials.gov. Study of COPD Subgroups and Biomarkers (SPIROMICS). NCT01969344. http://clinicaltrials.gov/ct2/show/NCT01969344?term5NCT01969344&rank51 Date last updated: April 24, 2014. Date last accessed: July 14, 2014. DOI: 10.1183/09059180.00004014